Tomovation means innovation

'A playground for new concepts and ideas'

In 2003, Michael Friebe PhD launched the holding company TOMOVATION (neatly combining tomography and innovation). Back in 1993, Dr Friebe was the founder of Neuromed AG, which at the time was the biggest provider and seller of mobile diagnostic services and refurbished MRI and CT systems in Central Europe. This firm was subsequently bought by UMS AG.

Photo: Tomovation means innovation

Tomovation has a special focus in all its business activities - medical imaging – and particularly MRI. Currently, the firm holds equity investments in 10 tomography companies. ‘The company is difficult to describe, as it is a playground for new concepts and ideas in MRI service operations, niche-market product development, and financing,’ Dr Friebe said. ‘It has a small sales operation for innovative niche-market products, and owns several MRI and CT imaging centres in Central Europe.’

Refurbished MRI services (and occasionally CT and PET) from de-installation through to re-installation – and everything in between - is provided worldwide via its subsidiary Tomosystems, which is ISO certified and approved by most OEM companies. This company is headed by Stefan Hellwig - an industry veteran - and supported by Bastian Berkel.

The Tomovation group holds over 10 MRI product-related patents and currently is developing devices for image guided surgery (through ITP) and MRI injectors (through Tomoinject), which even work with 7T MRI systems and already have won a prestigious design award.
In coming months, the R&D business will be complemented with dedicated investment activities in tomography start-up firms, to be managed by Oliver Lehmkuehler PhD.

Helped by innovative financing concepts and recently begun shared mobile MRI and PET services, Tomovation itself continues to invest in PET and MRI imaging centres.
Details:
Tomovation GmbH, Behringhauser Str. 31,
D-44575 Castrop-Rauxel
Phone: +49-2305-97322-0. Fax +49-2305-97322-99.

17.11.2006

More on the subject:

Related articles

Photo

Sponsored • New Whitepaper

AI-Enabled Care Pathway: Shifting the Paradigm in Prostate Cancer Diagnosis

Prostate cancer is the second most common cancer in men worldwide. As clinical guidelines increasingly recommend MRI before biopsy, prostate MRI has become a critical decision point in the diagnostic…

Photo

News • Prophylactic post-treatment

MRI surveillance after SCLC helps patients avoid brain irradiation

After treatment for small-cell lung cancer (SCLC), patients often undergo prophylactic radiotherapy to prevent metastases in the brain. Now, a new study shows that MRI surveillance alone is enough,…

Photo

News • Collagen-targeted protein CA

New MRI agent to earlier detect lung cancer, hidden metastases

A research team has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.

Subscribe to Newsletter